Background: DPP-IV has a role in degradation of glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and gastric inhibitory polypeptide (GIP) which had been reported to reduce bone resorption. We investigated the pharmacodynamic effect of evogliptin, a DPP-IV inhibitor, on human bone metabolism in human using serum carboxy-terminal collagen crosslinks (CTX) as a biomarker of bone resorption. Method: […]
